Validation of Liquid Chromatography-Tandem Mass Spectrometry-Based 5-Plex Assay for Mucopolysaccharidoses

Mucopolysaccharidoses (MPSs) are rare lysosomal storage diseases caused by the accumulation of undegraded glycosaminoglycans in cells and tissues. The effectiveness of early intervention for MPS has been reported. Multiple-assay formats using tandem mass spectrometry have been developed. Here, we developed a method for simultaneous preparation and better measurement of the activities of five enzymes involved in MPSs, i.e., MPS I, MPS II, MPS IIIB, MPS IVA, and MPS VI, which were validated using 672 dried blood spot samples obtained from healthy newborns and 23 patients with MPS. The mean values of the enzyme activities and standard deviations in controls were as follows: &alpha
iduronidase (IDUA), 4.19 &plusmn
1.53 &micro
M/h
iduronate-2-sulfatase (I2S), 8.39 &plusmn
2.82 &micro
N-acetyl-&alpha
glucosaminidase (NAGLU), 1.96 &plusmn
0.57 &micro
N-acetylgalactosamine-6-sulfatase (GALNS), 0.50 &plusmn
0.20 &micro
and N-acetylgalactosamine-4-sulfatase (ARSB), 2.64 &plusmn
1.01 &micro
M/h. All patients displayed absent or low enzyme activity. In MPS I, IIIB, and VI, each patient group was clearly separated from controls, whereas there was some overlap between the control and patient groups in MPS II and IVA, suggesting the occurrence of pseudo-deficiencies. Thus, we established a multiplex assay for newborn screening using liquid chromatography tandem mass spectrometry, allowing simultaneous pretreatment and measurement of five enzymes relevant to MPSs.